am I the only one who found amylin harder than the injections
am I the only one who found amylin harder than the injections, and I want the answer with the reasoning attached rather than just the conclusion.
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.
The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.
If two or three other people have done the same thing we might actually learn something. Alone it is an anecdote.
best — the order this archive was captured in
Independent result added to the log. Thank you for paying for it — there are very few on this compound.
Yes. Anyone reading this board should hold their conclusions loosely until phase 3 reports.
Which trial and which readout?
How many separate lots has anyone here tested?
Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.
Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.
I would not extrapolate the tolerability profile from the monotherapy arm to the combination. The trials report them separately for a reason.
Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.
Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same recepto
Disagreeing with this line: that figure is from a combination arm and is being quoted as monotherapy.
read the combination arms separately from the monotherapy arms
Monotherapy arm or combination arm?
Carried an assumption over from the tirzepatide board and was corrected within an hour. Deserved.
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.
Read the combination paper twice before saying anything here. The monotherapy and combination arms tell genuinely different stories.
Is there any independent purity data on this compound that you have seen?
Agreed — it is an amylin analogue and importing intuitions from the incretin boards produces confident nonsense.
amylin and GLP-1 are not redundant pathways
Correction: that is the combination programme, not the monotherapy readout. Different arms, different numbers.
REDEFINE is the combination programme
REDEFINE is the combination programme
Adding the standing caveat — nothing here is approved standalone and research material is not for human use.
the co-agonism argument is about complementary mechanisms
Are you comparing against a GLP-1 monotherapy result? They are not comparable.
- 1Independent purity data on this compound is sparse compared with the older…10 comments in this branch · started by u/runa_grimaldi